Rice Hall James & Associates, LLC Ocuphire Pharma, Inc. Transaction History

Rice Hall James & Associates, LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 07, 2024	SELL	$1.51 - $2.23 $103,277 - $152,523	-68,396 Reduced 23.42%	223,589 $342,000
Q1 2024 Apr 23, 2024	SELL	$1.89 - $3.27 $528,806 - $914,919	-279,792 Reduced 48.93%	291,985 $586,000
Q4 2023 Feb 08, 2024	SELL	$2.59 - $3.64 $665,244 - $934,937	-256,851 Reduced 31.0%	571,777 $1.72 Million
Q3 2023 Nov 02, 2023	SELL	$3.35 - $4.33 $69,204 - $89,449	-20,658 Reduced 2.43%	828,628 $2.78 Million
Q2 2023 Jul 24, 2023	BUY	$3.63 - $6.38 $145,813 - $256,278	40,169 Added 4.96%	849,286 $3.69 Million
Q1 2023 May 11, 2023	BUY	$3.01 - $3.85 $9,180 - $11,742	3,050 Added 0.38%	809,117 $3.03 Million
Q4 2022 Jan 27, 2023	BUY	$2.04 - $3.53 $542,066 - $937,988	265,719 Added 49.18%	806,067 $0
Q3 2022 Nov 01, 2022	BUY	$1.82 - $2.79 $387,394 - $593,862	212,854 Added 64.99%	540,348 $1.09 Million
Q2 2022 Aug 08, 2022	BUY	$1.8 - $3.25 $328,442 - $593,021	182,468 Added 125.82%	327,494 $629,000
Q1 2022 May 05, 2022	BUY	$2.75 - $4.39 $34,630 - $55,283	12,593 Added 9.51%	145,026 $470,000
Q4 2021 Feb 14, 2022	BUY	$3.4 - $5.19 $450,272 - $687,327	132,433 New	132,433 $494,000

2.58M

14.1K

800

Ticker OCUP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 20,579,800
Market Cap $20.2M
Description
Ocuphire Pharma, Inc., a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of refractive and retinal eye disorders. Its lead product candidate is Nyxol eye drops, a once-daily preservative-free eye drop formulation of phentolamine mesylate, which is in Phase III clinical tr...

Get notified when there are updates to the investment portfolio of Rice Hall James & Associates, LLC, based on Form 13F filings with the SEC.

Stay updated on Rice Hall James & Associates, LLC with notifications on news.